GRIK Therapeutics的封面图片
GRIK Therapeutics

GRIK Therapeutics

生物技术研究

Boston,Massachusetts 500 位关注者

Closing the biggest gap in Neuroscience therapeutics at the intersection of novel biology and advanced computation.

关于我们

GIRK Therapeutics is a pre-clinical stage therapeutics company focused on leveraging and integrating computation, electrophysiology and cortical circuit neurobiology to create the next generation of highly selective molecules for diseases with unmet needs. Harnessing the complexity of ion channels we have built a computational platform that links the binding of allosteric modulators to ion channel function, in-silico. With this approach we can generate treatments for neuroscience and brain health diseases that have been historically difficult to treat efficaciously.

所属行业
生物技术研究
规模
2-10 人
总部
Boston,Massachusetts
类型
私人持股
创立
2022
领域
Neurobiology 、Biotechnology、Pharmaceutical Science、Pharmacology、Rare Disease、Electrophysiology、Ion Channels、Neuroscience、CNS、Epilepsy、Computational Models、Drug Discovery、Molecular Dynamics和Psychiatric

地点

GRIK Therapeutics员工

动态

  • Thank you FDA for all you do for patients. As we hope to advance therapies for #Epilepsy including #DevelopmentalandEpilepticencephalopathy #DravetSyndrome #InfantileSpasms and other rare epilepsies, we rely on the FDA to continue to do their job of ensuring new therapies are safe and effective for patients in need!

    查看No Patient Left Behind的组织主页

    4,687 位关注者

    What does FDA’s scientific expertise and regulatory transparency mean to you and your family? Thank you Shehnaaz Suliman, M.D. (MB ChB), M.B.A., M.Phil., Gunnar Esiason, and Peter Kolchinsky for sharing how the FDA works hard with industry and innovators to ensure new, safe, and effective medicines reach U.S. patients. While there is room for improvement and greater efficiency at the FDA, there is a lot to be proud of. Thanks for all the work they do to keep the American public safe and healthy. We look to them as partners in the ongoing effort to help the U.S. expand its global leadership in biomedical innovation. Watch the video and sign the support letter here:?https://lnkd.in/gDa695rB

  • Thanks BioLabs for hosting and having GRIK Therapeutics participate. Bridging the global biotech ecosystem ! Great to be along side some amazing Boston based companies PathCision Medicine Neoclease and our Japenese and Korean counterparts!

    查看BioLabs的组织主页

    16,423 位关注者

    Rapid-Fire Pitch: Bridging Innovation Between Japan & US Biotech Communities! Join us on ??? Thursday, January 23, 2025, ?? 4:00 to 7:00 PM, to discover biotech innovations from #Japan and the #US. Entrepreneurs will showcase their innovative solutions addressing critical unmet medical needs in an 8-minute pitch format. Whether you're an investor, scientist, or professional, this is your chance to network, collaborate, and shape the future of global healthcare. ?? ?? In-Person & Live Webinar Options Available Secure your spot now - links in the comments below ?? #BioLabs #KLSAP #Networking #EnablingInnovationWorldwide

    • Networking Event & Rapid-Fire Pitch: Join us to hear from Japanese and US entrepreneurs about their latest groundbreaking innovations.
  • Great way for any innovation in the Epilepsy space to get backed by some of the most prestigious foundations and organizations in this area. GRIK Therapeutics loves to see so much focus and attention given to changing the outcome for so many affected patients. Iaso Ventures Epilepsy Foundation #Epilepsy #Innovation #Biotech

    查看Epilepsy Foundation的组织主页

    30,509 位关注者

    The 2025 Epilepsy Foundation Shark Tank Competition is now accepting Letters of Intent (LOIs)! If you have a bold, groundbreaking idea to improve epilepsy treatment, care, or community outreach, this is your chance to drive real change. New for 2025, the competition features two prize categories: the Community Award, with a prize value of up to $50,000, and the Investment Award, offering up to $200,000 from the NeuroImpact Fund. Winners will gain international recognition and up to $250,000 in combined awards to bring their vision to life. Don’t miss the opportunity to shape the future of epilepsy care—submit your LOI by January 31, 2025, and learn more at www.epilepsy.com/sharktank.

    • 该图片无替代文字
  • This is an important move forward for computational and AI driven drug discovery by NVIDIA . The next few years will see amazing progress in this area ultimately providing patients with safer more effective drugs at shorter time scales and lower costs.

    查看Andrii Buvailo, Ph.D.的档案

    Science & Tech Communicator | AI & Digital | Life Sciences | Chemistry

    Yesterday, NVIDIA open sourced its BioNeMo Framework! It is a second open source annoucement in the AI for biology field in just a week (see my previous post for the other one). BioNeMo is a research platform designed to scale biomolecular AI research for drug discovery and molecular design. The platform provides tools to train and deploy large biomolecular models across high-performance computing environments, enabling advanced computation in labs with limited resources. Integration with Leading AI Models: AlphaFold2: Achieves a 5x speedup in protein structure predictions. DiffDock 2.0: Delivers a 6.2x faster prediction of molecular orientations with 16% higher accuracy. RFdiffusion & ProteinMPNN: Speeds up the design of protein therapeutics targeting specific molecules. NIM Microservices: Introduces optimized, secure, and scalable AI inference services deployable on-premises or in cloud environments. BioNeMo Blueprints: Provides modular workflows for virtual screening and small molecule design, reducing time and cost in AI-driven discovery processes. Acceleration Libraries: Includes new libraries like cuEquivariance, optimizing mathematical computations for chemical and biomolecular models. In a PR, NVIDIA sais the tool is already integrated by over 200 biopharma companies and startups. The infrastructure is also supported by partners like AWS, Deloitte, and Accenture for broader enterprise use. With this move, NVIDIA attempts to standardize and accelerate AI-driven workflows in computational biology and drug discovery. While NVIDIA is certainly pushing its own influence with this move and the open source strategy by large software develoers is not new, it is, in my opinion, beneficial for the drug discovery community at this point. Anyway, check the tool and code via a link in the comments ?? Image credit: NVIDIA

    • 该图片无替代文字
  • We are lucky to be part of the LabCentral community and broader biotech ecosystem. We wouldn't have been able to enter this amazing community without the support of Servier . Thank you to both organizations for supporting and driving innovation !

    查看施维雅的组织主页

    477,225 位关注者

    ?? For more than 10 years, LabCentral has been a game changer in the life sciences startup ecosystem. Located in the heart of Kendall Square Association, it offers shared laboratory spaces and state-of-the-art facilities to over 278 innovative startups. ? ?? With 20,000 square meters across six cutting-edge facilities, LabCentral provides essential resources and support for biotech companies to thrive. ? LabCentral's strategic partnerships with pharmaceutical groups, including Servier, facilitate valuable feedback and opportunities for collaboration, driving scientific discoveries and advancements. ? Discover more about LabCentral's impact on biotech innovation in our latest issue of #InsightsbyServier ?? https://bit.ly/3N2DxAw ? #WeAreServier #innovation #LabCentral

    • 该图片无替代文字
  • GRIK Therapeutics is excited to welcome Mike Ackley on board as Chief Development Officer (CDO). Mike is an experience #pharmacologist and #physiologist with deep background in #neuroscience and #IonChannels . His experience driving drugs to the clinic will be pivotal in ensuring sound preclinical, clinical and regulatory strategies are in place and milestones are met. There is no one better to help us drive our initial program for #epilepsy to the clinic and help us leverage new targets for other diseases with unmet medical need.

    • 该图片无替代文字
  • Linking binding of a compound to biological function is the core of GRIK Therapeutics #IonChannel computational platform. The insights we can derive from tracking protein trajectories and ion flow goes well beyond what most computation does currently in #DrugDiscovery. We are excited to continue to share data that will help drive our #Neuroscience indications including #epilepsy #pain #psyciatric and other #CNS disorders. #biotech #techbio

    • 该图片无替代文字
  • GRIK Therapeutics is proud to be part of the Amazon Web Services (AWS) #ActivateProgram. This program through #AWS is committed to making it faster, easier, and more cost effective to startup and succeed. The potential for companies like GRIK Therapeutics to disrupt our industry and tackle real problems has never been greater, so the ability to build and scale with minimal cost and maximum support is paramount. Thank you Amazon Web Services (AWS) and the teams supporting us in this journey to change CNS disease treatment. #DrugDiscovery #ComputationalDrugDiscovery #MolecularDynamics #StructuralBiology #CloudComputing #IonChannel #CNS #Neuroscience #RareDisease

    • https://aws.amazon.com/startups/showcase/startup-details/7765e527-48d6-43f2-afa4-dd02fe13314a
  • 查看GRIK Therapeutics的组织主页

    500 位关注者

    GRIK Therapeutics is excited to announce its membership in the NVIDIA Inception Program. This will allow GRIK Therapeutics to significantly scale our computational ion channel platform that links the binding of novel chemical matter to the biological function of this protein class in silico. With this, we can accelerate ion channel drug discovery beyond current capabilities in the field using our computational models informed by novel biology. This program will help us create the necessary paradigm shift for drugging these proteins and bringing new treatments to patients quicker. Thank you NVIDIA for your work supporting startups! #NVIDIAInception #IonChannel #DrugDiscovery #ComputationalBiology #StructuralBiology #Neuroscience #Epilepsy #Psychiatric #Neurology

    • #NVIDIAInception #IonChannel #DrugDiscovery #ComputationalBiology #StructuralBiology #Neuroscience #Epilepsy #Psychiatric #Neurology
  • Great week at #SfN24 ! GRIK Therapeutics was encouraged to see the progress in #ionchannel #pharmacology and #drugdiscovery. We are excited to consider new partnerships to keep driving the next generation of ion channel modulator drugs for a variety of #Neurological #psychiatric and #neurodevelopmental diseases and disorders.

    查看Society for Neuroscience的组织主页

    123,817 位关注者

    "Welcome to Neuroscience 2024– it's great to be here together! This conference is a unique snapshot of all the work neuroscientists are excited about condensed into one exhilarating week.” Read more from Marina Picciotto, PhD, SfN President, in the #SfN24 Program and Exhibit Guide. ?? https://bit.ly/3NkjxsV

    • 该图片无替代文字

相似主页

查看职位